Partnering Inflammation/Autoimmune Drugs Offers Sizzle And Steak
Executive Summary
As Big Pharma companies back away from developing primary care products because of rising development costs and regulatory risk, they are increasingly turning to specialty medicines to fill their pipeline holes. One therapeutic area of particular interest: the inflammation/auto-immune space
You may also be interested in...
Veloxis Hopes Novel Slow-Release Tacrolimus Will Showcase Bioavailability Boost Of “Flat Kinetics”
Veloxis Pharmaceuticals A/S, aka LifeCycle Pharma, is a step closer in its plan to market a slow-release version of blockbuster immunosuppressant tacrolimus that is not substitutable by the handful of generics that have become available since Astellas Pharma Inc.'s branded Prograf lost U.S. patent protection in 2009.
Veloxis Hopes Novel Slow-Release Tacrolimus Will Showcase Bioavailability Boost Of “Flat Kinetics”
Veloxis Pharmaceuticals A/S, aka LifeCycle Pharma, is a step closer in its plan to market a slow-release version of blockbuster immunosuppressant tacrolimus that is not substitutable by the handful of generics that have become available since Astellas Pharma Inc.'s branded Prograf lost U.S. patent protection in 2009.
Bristol Pays $85 Million Upfront To Acquire Rheumatoid Arthritis Compound From Alder
The deal also requires Bristol to make an equity investment of up to $20 million should Alder go public.